RE-DUAL PCI – In Review

Published: 26 June 2020

  • Views:

    Views Icon 143
  • Likes:

    Heart Icon 7

Overview

This educational series looks at emerging data from the RE-DUAL PCI trial programme relating to switching anticoagulant strategy and sub-analyses data on diabetics with atrial fibrillation post-PCI

This video series was funded by an unrestricted educational service from Boehringer Ingelheim.

Learning Objectives

  • Understand the latest data in relation to the NOACs and its implication on selected subgroups of populations.
  • Interpret the new data on the treatment of patients with atrial fibrillation and when to apply dual vs triple therapy treatment.
  • Understand the implementation of the emerging data and which patient groups should be treated differently.

More from this programme

Part 1

RE-DUAL PCI – Switching of NOACs after PCI in patients with Atrial Fibrillation

Part 2

RE-DUAL PCI – Diabetes Sub-group Analysis

Faculty Biographies

Jur ten Berg

Jur ten Berg

Prof Jur ten Berg is Head of the St Antonius Center for Platelet Function Studies at the St Antonius Hospital, The Netherlands, where he also serves as Director of the Cardiology Training Programme. He has published over 400 peer-reviewed articles.

View full profile